Saturday, May 14, 2022 | 8 A.M. – 12:50 P.M. CST
Led by experts of the University of Chicago Medicine, this activity aims to help participants examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rationale for and results of studies that include novel agents targeting oncogenic relevant molecular alterations for the treatment of patients with advanced cancer. This knowledge will enable participants to appropriately utilize new treatments available to cancer patients, provide support for current and future oncology clinical trials, and become stronger leaders in the area of oncology research.
At the conclusion of this activity, participants will be able to:
- State the clinical effects of novel experimental agents including but not limited to immunotherapeutic approaches other than PD1 and CTLA4 checkpoint inhibitors, nuclear hormone receptor modulating agents, and epigenetic targeted drugs;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches including novel PET tracer imaging and circulating tumor DNA assays;
- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- Discuss advances in the use of systemic therapies for cancer including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.
Register here: https://cme.uchicago.edu/CDTS2022#group-tabs-node-course-default6
For more information, contact Debby Stoit at firstname.lastname@example.org or call 773-702-2698.